BPOM Launches Counterfeit Drug Monitoring Platform

Enhancing Public Awareness and Safety

The Indonesian Food and Drug Authority (BPOM) has introduced a dedicated Counterfeit Drug Risk Communication Channel as part of its efforts to combat the circulation of counterfeit medicines. This new platform serves as an official source of information regarding counterfeit drug findings, including details about product identities, distribution methods, health impacts, and legal actions taken by the authority.

Key Features of the New Platform

1. Public Access: The information is available through BPOM's official website (https://www.pom.go.id/hot-issue/obat-palsu) and official social media channels.
2. Comprehensive Information: Includes photos of counterfeit products, details about their distribution, health risks, and legal actions taken.
3. Public Education: Aims to enhance public awareness about the dangers of counterfeit drugs and help consumers differentiate between authentic and fake products.

Global Context and WHO Involvement

The issue of counterfeit drugs is a serious global concern, particularly in low- and middle-income countries. The World Health Organization (WHO) estimates that approximately 1 in 10 medical products circulating in these countries are substandard or falsified. WHO has been actively encouraging regulatory authorities worldwide to communicate findings about counterfeit drugs to the public as part of broader efforts to educate and empower consumers.

BPOM's Commitment to Combating Counterfeit Drugs

BPOM Head, Taruna Ikrar, emphasized that this new channel represents the agency's commitment to eradicating counterfeit drug circulation through effective risk communication. By providing accurate and accessible information, BPOM aims to protect public health and safety while fostering a more informed community regarding the risks associated with counterfeit pharmaceuticals.